Patient Power Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed lower rates of CLL patients receiving certain fungal infections if Bruton tyrosine kinase (BTK) inhibitors were part of their treatment plan, versus CLL patients who did not have BTK inhibitors as part of their therapy. Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidiscipl...
Patient Power Chronic lymphocytic leukemia (CLL) is one of the most common cancers that can be caused by POT1 tumor predisposition syndrome (POT1-TPDS). According to Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, POT1-TPDS is found in about 5% of patients who have CLL. This is a hereditary mutation, and there is a 50% chance per child that a parent wit...
Patient Power Nodular sclerosis Hodgkin lymphoma (NSHL) is the most common type of classical Hodgkin lymphoma (cHL), a cancer of the lymphatic system. Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, describes the different ways to treat NSHL and its generally favorable prognosis. Read the article here .
ASH Abstract Achievement Award- 2017
Young Investigator Travel Grant Recipient, Society of Hematologic Oncology (SOHO) Annual Meeting- 2017
Recognition Award, Wayne State University 2016 In the area of Citizenship And Academic Achievement
Clinical Research Award, Wayne State University - 2015
Young Achiever Award, American College of Physicians National Conference- 2014